Selection and characterisation of FVIII-specific single chain variable fragments

Hamostaseologie

Volumn 33, Issue SUPPL.1, 2013, Pages

  Naumann, A ^a   Scherger, A K ^a   Neuwirth, J ^a   Orlowski, A ^a   Kahle, J ^a   Schwabe, D ^a   Konigs C ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Fviii; Haemophilia A; Igg subclasses; Inhibitors; Phage display

Indexed keywords

BLOOD CLOTTING FACTOR 8; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; HUMAN; IMMUNOLOGICAL TOLERANCE; MAMMAL CELL; MOLECULAR CLONING; MOLECULAR LIBRARY; PHAGE DISPLAY; PROGNOSIS; PROTEIN DOMAIN;

FVIII INHIBITORS; HAEMOPHILIA A; IGG SUBCLASSES; PHAGE DISPLAY;

BLOOD COAGULATION; DRUG DESIGN; FACTOR VIII; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84888425894     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619801     Document Type: Article

References (19)

1. Biggs R, Austen DE, Denson KW et al. The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs. Br J Haematol 1972; 23: 137-155.
2. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-- twenty years' 'bonn protocol'. Vox Sang 1996; 70 (Suppl 1): 30-35.
3. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
4. Fulcher CA, de Graaf Mahoney S, Roberts JR et al. Localization of human factor FVIII inhibitor epi- topes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82: 7728-7732.
5. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-518.
6. Gitschier J, Wood WI, Goralka TM et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-330.
7. Goletz S, Christensen P, Kristensen P et al. Selection of large diversities of antiidiotypic antibody fragments by phage display. J Mol Biol 2002; 315: 1087-1097.
8. Healey JF, Lubin IM, Nakai H et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995; 270: 14505-14509.
9. Hoots WK. Pathogenesis of hemophilic arthropathy. Semin Hematol 2006; 43: S18-S22.
10. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
11. Kehoe JW, Kay BK. Filamentous phage display in the new millennium. Chem Rev 2005; 105: 4056-4072.
12. Kessel C, Königs C, Linde R et al. Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. Mol Immunol 2008; 46: 8-15.
13. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-3996.
14. Mannucci PM, Tuddenham EG. The hemophilias-- from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-1779.
15. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: a review. Semin Thromb Hemost 2003; 29: 69-76.
16. Markovitz RC, Healey JF, Parker ET et al. The diversity of the immune response to the A2 domain of human factor VIII. Blood 2013; 121: 2785-2795.
17. Schirrmann T, Büssow K. Transient Production of scFv-Fc Fusion Proteins in Mammalian Cells. Antibody Engineering 2010; 387-400.
18. Van Helden PM, van den Berg HM, Gouw S et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol 2008; 142: 644-652.
19. Whelan SF, Hofbauer CJ, Horling FM et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121: 1039-1048.